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Abstract
Activin has emerged as an important player in different types of
cancer, but the underlying mechanisms are largely unknown. We
show here that activin overexpression is an early event in murine
and human skin tumorigenesis. This is functionally important,
since activin promoted skin tumorigenesis in mice induced by the
human papillomavirus 8 oncogenes. This was accompanied by
depletion of epidermal cd T cells and accumulation of regulatory
T cells. Most importantly, activin increased the number of skin
macrophages via attraction of blood monocytes, which was
prevented by depletion of CCR2-positive monocytes. Gene expres-
sion profiling of macrophages from pre-tumorigenic skin and
bioinformatics analysis demonstrated that activin induces a gene
expression pattern in skin macrophages that resembles the pheno-
type of tumor-associated macrophages in different malignancies,
thereby promoting angiogenesis, cell migration and proteolysis.
The functional relevance of this finding was demonstrated by anti-
body-mediated depletion of macrophages, which strongly
suppressed activin-induced skin tumor formation. These results
demonstrate that activin induces skin carcinogenesis via attraction
and reprogramming of macrophages and identify novel activin
targets involved in tumor formation.
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Introduction
Epithelial skin cancers, in particular basal and squamous cell carci-
nomas (BCC and SCC), are the most frequent types of cancer in
humans, and they are diagnosed in 2–3 million people worldwide
every year. Due to the increased life expectancy, the enhanced sun
exposure, and the treatment of organ transplant patients with
immunosuppressive compounds, the incidence of epithelial skin
cancer is continuously increasing (Griffin et al, 2016). Cutaneous
SCCs often develop from precursor lesions, of which actinic kerato-
sis (AK) is the most frequent one. Thus, it has been estimated that
65% of cutaneous SCCs arise from AK (Criscione et al, 2009). AK
develops at multiple sites, in particular in sun-exposed skin, and its
treatment is important due to the risk of malignant transformation
(Werner et al, 2013). Importantly, it is generally difficult to predict
whether an AK lesion will progress to SCC, and it is therefore impor-
tant to identify biomarkers that indicate a high risk for malignant
progression. This requires a thorough understanding of the path-
omechanisms underlying AK development and progression and the
identification and functional characterization of the involved cell
types and genes/proteins. Some of them may represent novel targets
for therapeutic intervention. They include proteins that directly
affect proliferation, survival and migration of keratinocytes and
their malignant transformation, but also proteins that act on various
components of the tumor stroma. Among the latter is the growth
and differentiation factor activin, a member of the transforming
growth factor b (TGF-b) family. Activins are homo- or heterodimers
composed of two b chains, with activin A (bAbA) being the most
abundant and best-characterized variant (Chen et al, 2006). The
activity of activins is inhibited through binding to the secreted
glycoproteins follistatin or follistatin-related protein in the extracel-
lular environment (Xia & Schneyer, 2009). Activins signal via
heterotetrameric receptor complexes consisting of type I and type II
receptors, which are transmembrane serine/threonine kinases
(Chen et al, 2006).
We previously showed that activin is strongly upregulated in
murine and human skin wounds and in human BCCs and SCCs
(Hubner et al, 1996; Antsiferova et al, 2011). This is functionally
important, since overexpression of activin in keratinocytes of trans-
genic mice accelerated the wound healing process (Munz et al,
1999), but also promoted skin carcinogenesis and malignant
progression of existing tumors in a murine skin cancer model where
tumors are induced by a combination of the mutagen 7,12-dimethyl-
benzo(a)anthracene (DMBA) and the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Antsiferova et al, 2011).
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Interestingly, when the activin-overexpressing mice were mated
with transgenic mice expressing a dominant-negative activin recep-
tor mutant in keratinocytes, tumor development was not inhibited,
but rather mildly increased. These findings demonstrate that activin
does not promote tumorigenesis via keratinocytes, but rather has a
mild tumor-suppressive effect on these cells. By contrast, activin
obviously potentiates the oncogenic action of DMBA/TPA by gener-
ation of a pro-tumorigenic microenvironment. The latter involves
loss of tumor-suppressive cd T cells in the epidermis and a
concomitant increase in cutaneous ab T cells and Langerhans cells
(Antsiferova et al, 2011). However, it is unknown whether these
cells are indeed functionally involved in the tumor-promoting effect
of activin, and whether activin has additional, and possibly even
more important cellular targets. In addition, it remains to be
determined whether activin promotes skin tumorigenesis in more
physiologically relevant tumor models and whether it is required at
an early or late stage of skin cancer development. Most importantly,
the molecular targets of activin in the affected cells of the tumor
microenvironment remain largely unknown.
Here, we show that activin overexpression is an early event in
murine and human skin carcinogenesis and that increased levels of
activin strongly promote formation of skin tumors induced by the
human papillomavirus 8 (HPV8). We provide functional evidence
for a crucial role of macrophages in the pro-tumorigenic effect of
activin. Finally, we provide the first genome-wide RNA profiling
data of macrophages isolated from pre-tumorigenic lesions, which
identified novel activin target genes and revealed that activin
induces a pro-tumorigenic macrophage phenotype.
Results
Activin A is overexpressed in pre-cancerous skin lesions
To determine whether upregulation of activin expression occurs
early during skin cancer development, we analyzed the expression
of the activin bA subunit (INHBA) in biopsies of patients with
histopathologically well-characterized AK (Dataset EV1). INHBA
mRNA levels were two- to eightfold elevated in 7 out of 21 AK biop-
sies as compared to normal human skin (Fig 1A). This finding
suggests that the strong increase in INHBA expression seen in estab-
lished skin cancers as compared to healthy skin (Antsiferova et al,
2011) is an early event during skin tumorigenesis.
HPV8 has been associated with development of non-melanoma
skin cancer (Karagas et al, 2006), and higher HPV8 virus loads were
observed in AK (Weissenborn et al, 2005). To determine whether
HPV8-induced tumorigenesis is associated with an increase in
activin expression, we made use of mice expressing the oncogenes
of HPV8 in keratinocytes under the control of the keratin 14
promoter (HPV8/wt mice). These mice spontaneously develop
benign skin papillomas (Schaper et al, 2005). There was no signifi-
cant increase in Inhba mRNA levels in the mildly hyperplastic skin
of HPV8/wt compared to control (wt/wt) mice, but a strong upregu-
lation was seen in established papillomas of HPV8/wt mice
(Fig 1B). Concomitantly, mRNA levels of follistatin were mildly
reduced in the papillomas (Fig EV1A), suggesting that the overex-
pressed activin is functionally active. Immunostaining identified the
tumor cells as well as keratinocytes of the normal epidermis,
endothelial cells and other stromal cells as the sources of activin
(Fig 1C–E). This expression pattern is similar to the one observed in
human SCCs (Antsiferova et al, 2011) and consistent with the
expression of INHBA in tumor cells of AK and SCC patients isolated
by laser capture microdissection (Lambert et al, 2014).
Activin A promotes HPV8-induced skin tumorigenesis in mice
To determine the consequence of activin overexpression in kerati-
nocytes for HPV8-induced skin tumorigenesis, we inter-crossed
HPV8 mice with mice overexpressing the activin bA subunit in
keratinocytes under the control of the keratin 14 promoter (Act
mice) (Munz et al, 1999). While Act mice never developed tumors
in the absence of an oncogenic stimulus (Antsiferova et al, 2011),
the double-transgenic progeny (HPV8/Act mice) showed a strong
increase in the incidence of spontaneously developing skin tumors
compared to HPV8/wt animals (Fig 1F), demonstrating that
activin potentiates the oncogenic action of the HPV8 transgene. In
the HPV8/Act group, the first lesions appeared on the ears at the
age of 10 weeks, and this was preceded by progressive epidermal
hyperplasia and keratinocyte hyperproliferation (Fig EV1B–E). By
week 27, all double-transgenic mice had developed tumors
(Fig 1F). In contrast, the first tumors in the HPV8/wt mice only
appeared at week 16, and by 80 weeks, only 60% of the animals
had developed tumors. The median age of tumor development
was 66.5 weeks for HPV8/wt mice and 13 weeks for HPV8/Act
mice. Similar to field cancerization in AK patients (Dotto, 2014),
several HPV8-induced lesions were usually detected in close prox-
imity in these mice, and they appeared in an area where the
epidermis was generally strongly hyperplastic (Fig 1H). Therefore,
it was not possible to calculate the tumor multiplicity. The tumors
appeared at various anatomical sites (Figs 1G and EV1F), with ear
skin, back skin and sites of mechanical irritation (eyelid, snout)
being most often affected in both groups. The majority of the
lesions were classified as acanthopapillomas or acanthopapillomas
with trichoepitheliomatous differentiation. The numbers of both
types of lesions were increased in the presence of the INHBA
transgene, and there was no major difference in the histopathol-
ogy between groups (Figs 1H and EV1G). Additionally, six tumors
(6.2%) from HPV8/Act, but none from HPV8/wt mice were
trichoepitheliomas (Fig EV1G). All lesions analyzed were benign
tumors. However, in accordance with the animal welfare regula-
tions, the mice had to be sacrificed when the tumors reached the
size of 1 cm2 or when the mice developed more than one tumor
with a size of more than 0.5 cm2. Therefore, it may well be that
invasive tumors would have developed in older animals and this
could have been affected by activin. The strong tumor-promoting
effect of activin in the HPV8 model did not result from higher
expression of the HPV8 transgene as shown by qRT–PCR analysis
of keratinocytes, which had been purified by magnetic cell separa-
tion (MACS; Fig EV1H).
Tumor formation in activin-overexpressing mice correlates with
loss of epidermal cd T cells and accumulation of ab T cells in the
ear skin
To identify the cell types involved in the pro-tumorigenic effect of
activin in the HPV8 model, we first analyzed the number of
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epidermal T cells expressing the cd T-cell receptor (TcR). These
immune cells, which protect against experimental skin tumorigene-
sis in mice (Girardi et al, 2001), are growth inhibited by activin A
in vitro and depleted from the skin of Act mice upon DMBA/TPA
treatment (Antsiferova et al, 2011). Immunostaining revealed a
strong reduction in the number of cd TcR+ cells in the ear epidermis
of 10-week-old wt/Act and even more in HPV8/Act mice compared
to wt/wt or HPV8/wt animals (Fig 2A and B), which correlated with
the appearance of tumors in the ear skin at this age. The remaining
cd T cells were activated as shown by the loss of their dendritic
morphology (Fig 2A) and by flow cytometry analysis for the activa-
tion marker CD69 (Fig EV2A; Appendix Fig S1A). Interestingly,
there was no reduction in cd T cells in the back skin, which corre-
lated with the lack of histological abnormalities in back skin at this
age (Fig EV2B and C).
Concomitant with the loss of cd T cells, there was a significant
increase in ab T cells in the ear, but not in the back epidermis of
HPV8/Act and wt/Act mice compared to wt/wt or HPV8/wt animals
(Figs 2C and EV2D). Both CD4+ and CD8+ cells contributed to the
increased number of ab T cells in the dermis and epidermis of the
ear skin (Figs 2D and E, and EV2E and F, and Appendix Fig S1B).
CD4+CD25+ TcRb+ cells were particularly abundant in the ear
epidermis of HPV8/Act mice (Fig 2F and Appendix Fig S1C),
whereas the increase in CD4+CD25+ TcRb+ cells in the dermis was
non-significant (Fig EV2G). This finding indicates accumulation of
activated effector or regulatory T cells (Tregs), particularly in the
epidermis of HPV8/Act mice. Immunofluorescence for the
Treg-specific transcription factor Foxp3 indeed revealed a striking
accumulation of these immunosuppressive cells in the activin-over-
expressing mice, in particular in the presence of the activin
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Figure 1. Activin A is overexpressed in benign skin tumor lesions and promotes HPV8-induced skin tumor development in mice.
A qRT–PCR analysis of RNA samples from normal human skin (NS) and AK for activin bA (INHBA), normalized to hypoxanthine phosphoribosyltransferase (HPRT).
Expression levels in one of the normal skin samples were set to 1. Scatter plots are shown. NS, N = 4; AK, N = 21. ns, non-significant (Mann–Whitney test).
B qRT–PCR analysis of RNA samples from normal back skin of wild-type mice (N = 4, n = 4), non-tumorigenic back skin from HPV8/wt mice (N = 7, n = 9), and
papillomas from HPV8/wt transgenic mice (N = 8, n = 11) for Inhba, normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Expression levels in one of
the wild-type back skin samples were set to 1. Statistical significance was determined using one-way ANOVA and Bonferroni’s multiple comparisons test of log-
transformed data. N, number of mice; n, number of biopsies.
C–E Sections from a tumor collected from a 64-week-old HPV8/wt mouse (C, D) or from non-tumorigenic skin of 5-week-old HPV8/wt mice (E) stained with an anti-
activin A antibody and counterstained with hematoxylin. E, epidermis; D, dermis; HF, hair follicle. Panel (D) shows a higher magnification of the boxed area in (C).
Scale bars: 200 lm (C) and 100 lm (D, E).
F Kinetics of tumor incidence in HPV8/wt and HPV8/Act mice; N = 20 mice per genotype. Statistical significance was determined using log-rank (Mantel–Cox) test.
G Age of the mice when the first tumors appeared on certain body sites. Each dot represents one tumor.
H Representative macroscopic pictures of ear tumors (left panel) and H&E-stained sections of ear acanthopapillomas (upper and middle panel) or an ear
acanthopapilloma with trichoepitheliomatous differentiation (lower panel). Boxed areas are shown at higher magnification in subsequent pictures to the right in
each horizontal picture panel. E, epidermis; D, dermis; C, cartilage. Scale bars: 200 lm (left panel), 100 lm (middle panel), or 50 lm (right panel).
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transgene (Fig 2G). The increased number of ab T cells most likely
resulted from the upregulation of different T-cell chemokines, in
particular chemokine ligand 22 (Ccl22) (Fig EV2H–J).
Depletion of CD4+ T cells does not reduce the tumor-promoting
effect of activin
As CD4+ T cells enhanced neoplastic progression in HPV16-
induced skin cancer (Daniel et al, 2003) and promoted skin
tumorigenesis in DMBA/TPA- and UV-induced skin cancer
models (Yusuf et al, 2008; Nasti et al, 2011), and because of the
increase in CD4-positive Tregs, we intercrossed Act and HPV8
with CD4-deficient mice and analyzed spontaneous tumorigenesis
in the single, double, and triple mutant progeny. Surprisingly,
depletion of CD4+ cells caused a slight, albeit non-significant
increase in tumor incidence in wt/HPV8 mice, indicating that
CD4+ T cells are rather tumor-suppressive in the HPV8 model
under our experimental conditions. Most importantly, depletion
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Figure 2. Depletion of epidermal cd T cells and accumulation of ab T cells in the ear skin of activin-overexpressing mice.
A, B Representative pictures of ear sections from 10-week-old mice stained for dTcR (green) and counterstained with Hoechst (blue) (A), and quantification of dTcR+
cells in the ear epidermis (B). Dotted lines indicate the epidermal–dermal border. Scale bar: 20 lm. N = 6 wt/wt mice, N = 7 HPV8/wt mice, N = 6 wt/Act mice,
and N = 8 HPV8/Act mice.
C Quantification of bTcR+ cells in ear skin cryosections from 10-week-old wt/wt (N = 5), HPV8/wt (N = 5), wt/Act (N = 8) or HPV8/Act (N = 8) mice.
D–F Percentage of viable CD4+ bTcR+ (D), CD8+ bTcR+ (E) or CD4+CD25+ (F) cells among all epidermal cells analyzed by flow cytometry. Results from five experiments
with ears pooled from at least three mice per genotype are shown. Representative flow cytometry scatter plots are shown in Appendix Fig S1A–C.
G Representative pictures of ear cryosections from 10-week-old mice stained with antibodies against Foxp3 (red) and counterstained with Hoechst (blue). Insert
shows higher magnification of the Foxp3-positive cells in wt/Act skin. Dotted lines indicate the epidermal–dermal border. Scale bar: 50 lm.
H Kinetics of tumor incidence in HPV8/Act/wt (N = 29), HPV8/Act/CD4KO (N = 10), HPV8/wt/wt (N = 23), and HPV8/wt/CD4KO (N = 22) mice per genotype. Statistical
significance was determined using the log-rank (Mantel–Cox) test; ns, non-significant.
Data information: Statistical significance was determined using one-way ANOVA and Bonferroni’s multiple comparisons test (B–F).
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of CD4+ T cells did not abolish the tumor-promoting effect of
activin (Fig 2H).
Activin A increases the number of macrophages in the ear skin
The striking increase in dermal cellularity in pre-cancerous ear skin
of HPV8/Act mice prompted us to determine the number of macro-
phages. Indeed, immunofluorescence staining revealed a strong
accumulation of CD206-positive macrophages in the dermis of the
hyperplastic ear skin of wt/Act and HPV8/Act mice, but not of
HPV8/wt mice (Fig 3A and B). This was confirmed by flow cytome-
try analysis using antibodies against the macrophage markers
MerTK and CD64 (Gautier et al, 2012) (Fig 3C and Appendix Fig
S1D). The increased numbers of macrophages in the skin of Act
mice, even in the absence of the HPV8 transgene, demonstrate that
activin rather than the HPV8 oncogenes is responsible for this accu-
mulation. The important role of activin in macrophage accumula-
tion was confirmed in the DMBA/TPA model, where the number of
macrophages was also significantly increased in Act compared to wt
mice after eight TPA treatments (Fig 3D).
As a substantial fraction of dermal macrophages is continuously
replenished by blood-borne precursors (Tamoutounour et al,
2013), we investigated the origin of skin macrophages that accu-
mulate in the ears of activin-overexpressing mice by mating of
K14-Act mice with CCR2-eCFP-DTR mice (Hohl et al, 2009). These
mice express enhanced cyan fluorescent protein (CFP) and the
diphtheria toxin receptor (DTR) under control of the C-C chemo-
kine receptor 2 (CCR2) promoter and allow monitoring of CCR2+
cells by analysis of CFP fluorescence. They also allow depletion of
these cells by systemic treatment of the animals with DT. Since
CCR2 is required for emigration of monocytes from the bone
marrow (Serbina & Pamer, 2006), depletion of this population
allowed us to determine whether the macrophages that accumulate
in the skin of Act mice are derived from the bone marrow. Deple-
tion of CCR2+ cells by injection of DT every second day during
1 week indeed dramatically reduced the number of MerTK+CD64+
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Figure 3. Activin promotes migration of CCR2+ macrophage precursors to the skin.
A, B Representative pictures of ear skin cryosections from 10- to 12-week-old mice stained with anti-CD206 antibodies (green) and counterstained with Hoechst (blue)
(A), and quantification of CD206+ area as a percentage of total dermal area (B) in wt/wt (N = 3), HPV8/wt (N = 7), wt/Act (N = 2), or HPV8/Act (N = 8) mice. The
basement membrane is indicated with a white dotted line.
C Abundance of MerTK+CD64+ macrophages analyzed by flow cytometry of normal or pre-cancerous ear skin from 12- to 16-week-old mice. N = 5–6. Representative
flow cytometry scatter plots are shown in Appendix Fig S1D.
D Quantification of CD206+ area as a percentage of total dermal area in wt (N = 7) and Act (N = 6) mice in back skin treated 8× with TPA (Antsiferova et al, 2011).
E Abundance of MerTK+CD64+ macrophages analyzed by flow cytometry of pre-tumorigenic ear skin from 12-week-old mice expressing the CCR2-CFP-DTR transgene
(wt/CCR2) or double-transgenic animals (Act/CCR2), untreated or treated with diphtheria toxin (+DT) three times every 48 h and analyzed 24 h after the last
injection. Percentage of CD45+CD11b+MerTK+CD64+ macrophages among live cells is shown. N = 3 control wt/CCR2 and Act/CCR2 mice; N = 4 DT-injected wt/CCR2
and Act/CCR2 mice. Representative flow cytometry scatter plots are shown in Appendix Fig S1E.
F, G Inflammatory thioglycollate-elicited peritoneal macrophages (F) or mouse peripheral blood monocytes (G) were isolated from wt mice and allowed to migrate for
24 h in a Transwell assay. Activin A 0.1 ng/ml (A0.1), 1 ng/ml (A1), or 10 ng/ml (A10) was added to the lower well. Alternatively, 10 ng/ml was added to the lower
well and the insert (A10/A10). Random migration to medium (ctrl) was set to 1 for each mouse; fold over control is shown. Log-transformed data were used for
statistical analysis. Results in (F) are representative of four independent experiments performed with eight mice in total (results obtained in one experiment
performed with three mice are shown). Results in (G) are combined from two independent experiments performed with monocytes isolated from pooled blood of at
least 13 wt mice.
Data information: Statistical significance was determined using one-way ANOVA and Bonferroni’s multiple comparisons test (B–E) or one-sample t-test after
log-transformation (F).
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cells in the ear skin of wt/CCR2 and Act/CCR2 mice (Fig 3E and
Appendix Fig S1E), indicating that the accumulation of macro-
phages in the skin is a result of increased influx of CCR2+ mono-
cytes. This is most likely a direct effect of activin as shown in
Transwell migration assays where recombinant activin A dose-
dependently increased the migration of monocyte-derived
inflammatory peritoneal macrophages (Fig 3F). However, when
activin A was present in the lower and the upper well of the
Transwell assay plate, macrophage migration was only marginal,
indicating that an activin gradient induces directional migration of
macrophages. Consistent with this finding, activin A also attracted
FACS-sorted blood monocytes (Fig 3G).
Activin induces a pro-migratory and tumor-promoting phenotype
in macrophages in vivo and in vitro
To determine the in vivo relevance of this finding and the potential
relevance for skin tumorigenesis, we isolated macrophages from the
pre-tumorigenic ear skin of wt/wt, HPV8/wt, wt/Act, and HPV8/Act
mice by FACS, and analyzed their expression profile by RNA
sequencing. This experiment was performed after transfer of our
mice to a new animal facility where the development of tumors was
delayed in HPV8/Act and in particular in HPV8/wt mice compared
to the old facility (Fig EV3A), most likely due to minor alterations in
the microbiome and/or environmental conditions. The new environ-
ment affected the onset of tumor formation, but not the strong pro-
tumorigenic effect of activin and the effect of activin on immune
cells. Therefore, we used pre-tumorigenic skin of 13- to 15-week-old
wt/wt, HPV8/wt, wt/Act, and HPV8/Act mice for the FACS-sorting
experiment (Fig EV3B), and we sequenced RNA samples from three
pools of 3–6 mice per genotype (Fig 4A). Each mouse was carefully
analyzed for any signs of tumor formation, and only mice without
tumors were used for the sorting experiment. We sorted F4/80+/
CD11b+ cells to obtain a broad coverage of the myeloid cell popula-
tion and to obtain a sufficient number of sorted cells from ear skin,
which was particularly difficult in mice lacking the activin transgene
(Fig 4B). The sorting confirmed that activin, but not the HPV8 trans-
gene, strongly enhances the number of macrophages in the skin
(Fig 4B).
The HPV8 transgene alone also did not affect the gene expres-
sion pattern in macrophages, but activin overexpression had a
dramatic effect on the expression profile of F4/80+CD11b+ cells,
both in the presence or absence of the HPV8 transgene
(Fig EV3C). Thus, 107 genes were differentially regulated
(FDR < 0.05, |log2ratio| > 1) in wt/Act vs. wt/wt mice, 80 genes
in HPV8/Act vs. HPV8/wt mice, and 128 genes in HPV8/Act vs.
wt/wt mice (Fig EV3C and D). Complete lists of differentially
regulated genes from different genotype comparisons are
presented in Dataset EV2. Analysis of the expression data con-
firmed that mouse skin macrophages express activin receptors
Acvr1, Acvr1b, Acvr2a, and Acvr2b (Fig EV3E), explaining their
responsiveness to activin A.
We then used Ingenuity Pathway Analysis (IPA) to determine
whether genes associated with certain functions or diseases are
enriched in the activin-regulated genes using all three genotype
comparisons: wt/Act vs. wt/wt; HPV8/Act vs. HPV8/wt; HPV8/Act
vs. wt/wt. Interestingly, genes associated with “cell movement” and
“activation of mononuclear leukocytes”, “adhesion of phagocytes”,
and “vasculogenesis” were significantly enriched, and their regula-
tion by activin corresponded with the predicted activation of these
functions in the sorted skin macrophages (Fig 4C). With regard to
disease association, genes annotated with “cancer” and—more
specific—”skin tumor” were significantly enriched and predicted to
be activated in the HPV8/Act vs. control, but not in the wt/Act vs.
Figure 4. Activin reprograms macrophages toward a TAM-like phenotype.
A Scheme of the experimental setup. Pre-tumorigenic ear skin from 3 to 6 mice per genotype was pooled, and macrophages were enriched by FACS sorting of
F4/80+CD11b+ cells and subjected to RNA sequencing. Each replicate represents one of three independent FACS experiments (n = 3).
B Analysis of FACS data of sorted macrophages shows the relative percentage of CD45+CD11b+F4/80+ cells in each genotype and the absolute number of sorted cells
used for RNA sequencing. Representative flow cytometry gating strategy for sorting is shown in Fig EV3B. N = 5–9. Statistical significance was determined using one-
way ANOVA and Bonferroni’s multiple comparisons test.
C Differential expression of genes was analyzed using the edgeR software package. IPA was performed with filtered lists of up- and downregulated genes that exhibited
an FDR value of < 0.1 in different genotype comparisons (wt/Act vs. wt/wt; HPV8/Act vs. HPV8/wt; HPV8/Act vs. wt/wt). The number of differentially expressed genes
used for analysis is indicated. Data are presented as pseudo-heatmap with magnitudes of activation Z-scores color-coded as indicated in the legend; all non-gray
comparisons are –log10(P-value) > 2.5 unless otherwise indicated.
D Gene set enrichment analysis (GSEA) was performed to compare transcriptomes of genotype comparisons (wt/Act vs. wt/wt; HPV8/Act vs. HPV8/wt; HPV8/Act vs. wt/
wt, [all]/Act vs. [all]/wt) to three published datasets of tumor-associated macrophages (TAM) (Ojalvo et al, 2009; Franklin et al, 2014; Galletti et al, 2016). Gene sets
are composed of top genes upregulated (TAM UP) or downregulated (TAM DOWN) in TAM vs. normal tissue macrophages. Positive normalized enrichment score (NES)
corresponds to enrichment of gene set in activin-upregulated genes; negative NES corresponds to enrichment in activin-downregulated genes. Data are presented as
pseudo-heatmap with magnitudes of NES color-coded as indicated in the legend; all non-gray comparisons are FDR < 0.10.
E Differential GSEA was performed on combined genotype comparison [all]/Act vs. [all]/wt and two datasets of human AK vs. normal skin (GSE2503; Nindl et al, 2006)
and GSE63107 to compare these transcriptomes to gene sets derived from top upregulated genes in these datasets (top); and gene sets derived from top upregulated
genes in datasets of differential human macrophage activation (IFN-c, TNF-a, LPS, IL-4 vs. non-treated) and selected human myeloid/lymphoid cell-type-specific gene
expression profiles (macrophage vs. monocyte, dendritic cell, and T cell) (Xue et al, 2014; bottom). Activin target genes enriched in the AK transcriptomes are shown
(right). Data are presented as pseudo-heatmaps with magnitudes of normalized enrichment scores (NES) and log2(fold change) color-coded as indicated in the
respective legends; all non-gray comparisons are FDR < 0.05 for NES and P < 0.10 for fold change.
F Venn diagram showing overlapping differentially expressed genes (FDR ≤ 0.05, |log2ratio| ≥ 1) in different genotype comparisons.
G Heatmap of 28 differentially expressed genes (FDR ≤ 0.05, |log2ratio| ≥ 1) overlapping in all three comparisons (wt/Act vs. wt/wt mice, HPV8/Act vs. HPV8/wt and
HPV8/Act vs. wt/wt). Genes with a published pro-tumorigenic function are highlighted in red.
Data information: Complete lists of differentially regulated genes from different genotype comparisons, including corresponding fold change and exact FDR values, are
presented in Dataset EV2. Complete list of diseases and functions identified by IPA for each genotype comparison, including exact P-values, is shown in Dataset EV3.
Complete original and filtered gene sets, ranked gene lists used for the GSEA, and original GSEA reports, including exact FDR and P-values, can be found in Dataset EV4.
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wt/wt comparison. The “cell proliferation of SCC cell lines” function
was both enriched and activated in all comparisons. The full list of
diseases and functions identified by IPA for each genotype compar-
ison can be found in Dataset EV3.
We next used gene set enrichment analysis (GSEA) (Subramanian
et al, 2005) to compare activin- and HPV8-dependent gene
expression profiles of sorted macrophages with published transcrip-
tomes of tumor-associated macrophages (TAMs). Remarkably,
genes regulated by activin in macrophages showed a significant
positive correlation with genes that were shown to be upregulated
in murine mammary TAMs in two independent studies (Ojalvo
et al, 2009; Franklin et al, 2014) and also in bone marrow TAMs
from mice with leukemia (Galletti et al, 2016) (Fig 4D). In contrast,
activin-regulated genes were negatively correlated with the genes
downregulated in TAMs and thus upregulated in normal tissue
macrophages.
To determine the potential relevance of our mouse RNA-seq data
for human AK, we made use of two sets of published RNA profiling
data from normal skin and AK samples (GSE63107; Nindl et al,
2006). We performed GSEA to assess the level of overall gene
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expression similarities between murine macrophages exposed to the
transgene-derived activin and total AK samples. Importantly, many
of the genes that were upregulated in mouse macrophages by
activin in vivo were strongly enriched in both AK datasets. Likewise,
genes upregulated in both AK datasets were enriched in activin-
stimulated murine macrophages (Fig 4E, top panel). Further
analysis of these data confirmed the upregulation of INHBA in AK
samples, together with several activin target genes in macrophages
that we had identified, including ARG1, F11R, MMP12, MMP14,
TGFBR1, and others (Fig 4E, right panel).
We also performed comparative GSEA on several relevant gene
sets derived from expression profiling experiments of in vitro stimu-
lated human macrophages and a subset of myeloid and lymphoid
cells in order to assess the potential contribution of these cell types
to the overall gene expression of AK samples and to compare them
to the macrophage phenotype seen in Act mice. Intriguingly, the
gene expression profile of classically activated macrophages (IFN-c
treated; Xue et al, 2014) was strongly enriched in our activin-
stimulated macrophages and in both AK datasets, while that of
alternatively activated macrophages (IL-4 treated) was not (Fig 4E,
bottom). GSEA revealed a monocyte gene signature in activin-
exposed macrophages that is also present in both AK datasets in
addition to other myeloid and lymphoid cell signatures, due to the
complex nature of the clinical samples. Overall, these results
suggest that monocyte recruitment and stimulation of macrophages
by activin may contribute significantly to the gene expression profile
and pathophysiology of human AK.
We then concentrated on the 28 genes that were differentially
regulated in all three genotype comparisons (24 up, four down;
FDR ≤ 0.05, |log2ratio| 1) (Fig 4F and G). A literature search for
these genes allowed us to assign them to the functional categories
“adhesion/migration”, “cancer-association”, “angiogenesis”,
“anti-microbial/effector function”, and “immunoregulation”, thus
mirroring the results from the IPA analysis (Appendix Table S1).
Consistent with the migratory phenotype of macrophages in
activin-transgenic mice, a class of genes that was strongly affected
by activin encodes proteins associated with cell migration. Among
them is CX3CR1, the fractalkine receptor that is expressed among
other cells on blood monocytes and is thought to mediate their
recruitment to non-inflamed tissues (Geissmann et al, 2003). We
confirmed the upregulation of Cx3cr1 mRNA in a separate set of
biological replicates (Appendix Fig S2A), and its expression was
strongly induced by activin A in peritoneal macrophages in vitro
(Fig 5A). Overexpression of several adhesion molecules (junctional
adhesion molecule A (F11r), integrin beta 5 (Itgb5), integrin alpha
L, (Itgal)), and of other proteins associated with cell migration
(Golgi membrane protein 1 (Golm1) and haematopoietic cell kinase
(Hck)), was also observed in the presence of the activin transgene
(Appendix Table S1).
Most interestingly, 8 out of 26 (31%) of the genes significantly
upregulated in all three comparisons have a documented pro-
tumorigenic function, are expressed by TAMs, or serve as a prog-
nostic marker of advanced/malignant cancers (Appendix Table S1,
highlighted in red in Fig 4G). One of them, Spp1, encodes osteo-
pontin, which promotes fibrotic processes such as scarring of skin
wounds (Mori et al, 2008) and tumorigenesis (Shevde & Samant,
2014). It was more than fourfold upregulated in macrophages
isolated from activin-overexpressing mice (Fig EV3D and E), and
its expression was strongly induced by activin A in peritoneal
macrophages in vitro (Fig 5B). We confirmed the increased expres-
sion of osteopontin by Western blot analysis of total ear lysates
(Fig 5C and D) and by immunofluorescence staining of ear skin
sections, where most of the staining co-localized with CD68+
macrophages (Fig 5E).
Although not significantly regulated in all genotype compar-
isons, arginase 1 (Arg1), which promotes skin tumorigenesis in
mice (Weber et al, 2016), was also strongly upregulated in the
presence of the Act transgene (Fig EV3D and E, and
Appendix Fig S2B). This is most likely a direct effect of activin,
since activin A induced the expression of Arg1 in resident and
inflammatory thioglycollate-elicited peritoneal macrophages
(Fig 5F).
▸Figure 5. Activin induces expression of pro-tumorigenic genes in macrophages, associated with a proteolytic microenvironment and vascular remodeling.A, B Expression of Cx3cr1 (A) and Spp1 (B) relative to Rps29 was analyzed by qRT–PCR in peritoneal macrophages, resident or inflammatory, treated in vitro with
10 ng/ml of activin A (Act) or untreated (Ctrl, arbitrarily set to 1). Results are combined from 2 to 5 independent experiments performed with cells pooled from at
least five wt mice.
C, D Western blot analysis of total ear protein lysates of 12- to 14-week-old mice for osteopontin (OPN) and GAPDH (C). Each lane represents an individual mouse
(n = 3). (D) Band intensities were quantified and normalized to GAPDH. The expression level in one of the wt mice was arbitrarily set to 1.
E Ear skin sections from 10-week-old mice stained with anti-CD68 (red) or anti-osteopontin antibody (green) and counterstained with Hoechst (blue). Osteopontin-
positive macrophages in wt/Act and HPV8/Act mice are indicated with arrows. Representative of N = 2 wt/wt and N = 3 HPV8/wt, wt/Act and HPV8/Act mice. Boxed
areas in top panel are shown at higher magnification in bottom panel. Scale bars: 100 lm (top) or 20 lm (bottom).
F Expression of Arg1 relative to Rps29 was analyzed by qRT–PCR in peritoneal macrophages, resident or inflammatory, treated in vitro with 10 ng/ml of activin A
(Act) or untreated (Ctrl, arbitrarily set to 1). Results are combined from 2 to 5 independent experiments performed with cells pooled from at least five wt mice.
G In situ gelatin zymography (top panel) and methylene blue staining (bottom panel) of the ear skin from 10-week-old mice. Representative images of 2–3 mice per
genotype are shown. Scale bar: 500 lm.
H, I Gelatin zymography of ear skin lysates from 10-week-old mice. Inverted image of a representative gel with samples from two (wt/wt) or three (HPV8/wt, wt/Act,
HPV8/Act) mice per genotype is shown in (H), quantification of the results obtained in two independent experiments is shown in (I). N = 5 wt/wt, N = 6 HPV8/wt,
wt/Act, and HPV8/Act mice.
J Representative pictures of ear skin from 10-week-old mice stained for MECA32 (red), LYVE1 (green), and counterstained with Hoechst (blue). Boxed areas in top
panel are shown at higher magnification in bottom panel. Scale bars: 100 lm (top) or 20 lm (bottom).
K, L Quantification of MECA32+ area (K) and average distance between MECA32+ vessels and basement membrane (BM) (L).
Data information: Statistical significance was determined using one-sample t-test of log-transformed data (A, B, F), one-way ANOVA, and Bonferroni’s multiple
comparisons test of log-transformed data (D) or one-way ANOVA and Bonferroni’s multiple comparisons test (I, K, L).
Source data are available online for this figure.
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Skin macrophages of activin-transgenic mice also showed a
strong overexpression of the gene encoding matrix metallopro-
teinase (MMP)-14, an activator of MMP-2 (Sato et al, 1994) (Figs 4G
and EV3D and E). This is likely to be functionally relevant as deter-
mined by in situ zymography. There was little or no gelatinolytic
activity in ear skin of 10-week-old wt/wt and HPV8/wt mice,
whereas the dermis of wt/Act, and especially of HPV8/Act animals
exhibited strong gelatinolytic activity (Fig 5G), a phenomenon that
is often associated with a pro-tumorigenic microenvironment
(Kessenbrock et al, 2010). In-gel gelatin zymography revealed that
this increase mainly results from MMP-2 activity, whereas pro- and
active MMP-9 were hardly detectable (Fig 5H and I). Macrophages
from activin-overexpressing mice also showed a strong upregulation
of Mmp12 (Figs 4G and EV3E), and a moderate increase in Mmp13
expression (Fig EV3E).
Given the important functions of MMP-13, -14, and -2, and of
osteopontin in tumor angiogenesis (Basile et al, 2007; Kudo et al,
2012; Kale et al, 2014), we analyzed the area and the size of the
blood vessels, but did not find significant changes in activin-overex-
pressing mice (Fig 5J and K, and data not shown). An obvious dif-
ference, however, was the accumulation of vessels in the upper
dermis in these mice, as evidenced by the significantly reduced
distance between MECA32+ vessels and the basement membrane
(Fig 5J and L). This finding suggests that the activin produced by
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keratinocytes directly or indirectly induced angiogenesis and
vascular remodeling in the underlying dermis.
Taken together, when overexpressed in the skin, activin not only
attracts monocytes to the dermis, but also affects their differentia-
tion, thereby inducing an expression profile that promotes migra-
tion, angiogenesis, and ultimately tumorigenesis.
Macrophage depletion delays spontaneous tumorigenesis in
Act/HPV8 mice
Finally, we determined whether the pro-tumorigenic effect of activin
is indeed macrophage-dependent. Therefore, we depleted these cells
by injecting HPV8/Act mice with an antibody against the receptor of
colony-stimulating factor 1 (CSF1R) twice per week prior to the first
manifestation of tumors (30–37-day-old mice) during a 5-week
period. For this purpose, we mated Act mice with HPV8 mice in a
FVB1 background, since tumors develop earlier in this mouse strain
compared to C57BL/6 mice (Schaper et al, 2005). Macrophage
depletion significantly delayed the spontaneous tumorigenesis in
HPV8/Act mice as determined by macroscopic analysis of both ears
(Fig 6A). This was confirmed by histopathological analysis of the
ear skin samples collected 3–4 days after the treatment. In the ear
sections that were analyzed (one section from each ear), we
detected acanthopapillomas in 4 out of 10 HPV8/Act mice treated
with control IgG, whereas we only observed intra-epithelial
neoplasia in the sections from the 10 macrophage-depleted animals.
Immunostaining confirmed the strong reduction in the number of
CD68+ or CD206+ cells in the ear skin compared to mice injected
with control rat IgG (Fig 6B and C). Thus, the strong increase in
tumor formation in Act mice is to a large extent dependent on
macrophages, which accumulate in the skin and acquire a pro-
tumorigenic phenotype in the presence of activin. The effect of
CSF1R antibody treatment on tumorigenesis in HPV8/wt mice could
not be determined, since these mice do not develop tumors within
this time frame (Fig EV3A) and since multiple injections per week
over many months were not possible because of animal welfare
reasons. Therefore, we cannot exclude the possibility that tumor
formation in HPV8/wt mice is also at least in part dependent on
macrophages, although these cells did not accumulate in the pre-
tumorigenic skin of HPV8/wt mice and their gene expression
pattern was not affected by the HPV8 transgene.
The reduced tumor formation upon macrophage depletion in
HPV8/Act mice was associated with a significantly reduced prolif-
eration rate of keratinocytes (Fig 6D and E). Consistent with this
finding, depletion of CCR2+ cells from Act/CCR2 mice using DT
(see Fig 3F) also reduced keratinocyte proliferation (Appendix Fig
S3A and B). Notably, macrophage depletion was accompanied by
a strong downregulation of Mmp12 mRNA (Fig 6F). This is consis-
tent with the efficient depletion of macrophages, since MMP-12,
which is also known as macrophage metalloelastase, is predomi-
nantly expressed in this cell type (Qu et al, 2011). In addition, we
found a significant reduction in the area of CD31+LYVE1 blood
vessels (Fig 6G and H) and a decreased number of blood vessels
(Fig 6G and I). These findings reveal that activin promotes skin
tumorigenesis at least in part via macrophages. They also strongly
suggest that activin promotes angiogenesis, proteolytic activity,
and keratinocyte proliferation at least in part via its effect on
macrophages.
Discussion
Here, we show a remarkable pro-tumorigenic effect of activin in the
early phase of skin tumorigenesis, which is mediated via activin-
induced attraction of monocytes and their differentiation into a
TAM-like phenotype. The early upregulation of activin during
epithelial skin tumorigenesis in mice and humans may be a conse-
quence of inflammation, since activin A expression is induced in
cultured keratinocytes by pro-inflammatory cytokines (Hubner &
Werner, 1996) and since AK lesions and also papillomas in HPV8-
transgenic mice are characterized by an inflammatory infiltrate
(Massone & Cerroni, 2015; Rolfs et al, 2015; M. Antsiferova and S.
Werner, unpublished data). Thus, activin seems to be particularly
relevant at the stage when benign tumors appear and further
progress. By contrast, there is little inflammation in the pre-tumori-
genic, but already mildly hyperplastic skin of HPV8-transgenic mice
(Rolfs et al, 2015), including a lack of macrophage accumulation,
which correlates with the lack of activin upregulation at this very
early stage.
The inflammation-induced increase in activin expression is func-
tionally important, since activin overexpression promoted the devel-
opment of skin papillomas in the DMBA/TPA and also in the HPV8
skin tumorigenesis model. In the future, it will be interesting to
determine whether overexpression of activin promotes malignant
conversion of AK lesions and could thus act as a biomarker for
lesions, which have a higher probability to progress to SCC. In
support of this hypothesis, we previously showed in the DMBA/
TPA model that activin promotes malignant conversion of existing
skin tumors (Antsiferova et al, 2011). However, a recent study
demonstrated that only 2.57% of AKs progress to SCC within a
4-year interval (Criscione et al, 2009), suggesting that overexpres-
sion of activin alone is not sufficient for progression into SCC.
Rather, the malignant progression likely requires additional muta-
tions and/or epigenetic alterations in keratinocytes. Nevertheless,
activin overexpression may be a relevant diagnostic parameter.
Upon progression of AK to SCC, a further increase in activin expres-
sion occurs (Antsiferova et al, 2011; Lambert et al, 2014), suggest-
ing that activin not only promotes malignant progression of early
lesions, but also growth and potentially malignant progression of
established SCCs.
Similar to the DMBA/TPA model, activin overexpression also
reduced the number of tumor-suppressive cd T cells and increased
the number of tumor-promotive Tregs in ear skin of HPV8-trans-
genic mice, which correlated with the appearance of skin tumors.
However, genetic depletion of CD4+ T cells did not rescue the pro-
tumorigenic effect of activin. It even slightly increased the tumor
incidence in wt/HPV8 mice, a finding that contradicts the tumor-
promotive role of CD4+ T cells in a HPV16 skin cancer model
(Daniel et al, 2003). The difference may be due to the different viral
transgenes and/or different hygiene conditions, since CD4+ T cells
from K14-HPV16 mice showed reactivity to Staphylococcus aureus
antigens and induced neutrophil infiltration, resulting in tumor
promotion. Unfortunately, interpretation of the result obtained with
the CD4-deficient mice is problematic, since the CD4+ T-cell popula-
tion not only includes Tregs, but also other types of T cells that may
induce an immune response against the tumor cells. Loss of both
populations may explain why we did not observe a major effect on
tumorigenesis in the presence of high activin levels. In the future, it
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Figure 6. Depletion of macrophages delays spontaneous tumorigenesis in HPV8/Act mice by reducing keratinocyte proliferation and angiogenesis.
A Kinetics of tumor incidence in HPV8/Act mice treated for 5 weeks with 50 mg/kg anti-CSF1R antibody (AFS98) or with control rat IgG. N = 10 mice per treatment
group.
B Representative pictures of anti-CD68- or anti-CD206-stained cryosections of ear skin from 10-week-old mice treated for 5 weeks with anti-CSF1R antibody or
control rat IgG. Scale bar: 100 lm.
C Quantification of the CD68+ or CD206+ area relative to total dermis area. N = 10 mice per treatment group.
D Representative pictures of anti-BrdU (green) and anti-K14 (red) stained cryosections of ear skin from 10-week-old mice treated for 5 weeks with anti-CSF1R
antibody or control rat IgG. Scale bar: 50 lm.
E Quantification of BrdU+ keratinocytes per mm of basement membrane. N = 8 anti-CSF1R-injected mice; N = 4 rat IgG-injected mice.
F Expression of Mmp12 relative to Rps29 was analyzed by qRT–PCR in total ear skin from mice treated with anti-CSF1R antibody or with rat IgG. Expression in one of
the IgG-injected mice was set to 1. N = 10 per group.
G Representative pictures of the ear skin from 10-week-old mice treated for 5 weeks with anti-CSF1R or control rat IgG, stained for CD31 (red), LYVE1 (green), and
counterstained with Hoechst (blue). Boxed areas are shown at higher magnification in the top right corner. Scale bar: 100 lm.
H, I Quantification of CD31+LYVE1 area (H) and number of CD31+LYVE1 vessels (I).
Data information: White dotted lines in (B, D, and G) indicate the basement membrane. Statistical significance was determined using log-rank (Mantel–Cox) test (A),
Mann–Whitney test (C, E, H, I) or unpaired t-test after log-transformation (F).
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will therefore be interesting to determine the consequences of the
selective loss of Tregs. Furthermore, a potential role of CD8+ T cells
in the pro-tumorigenic effect of activin should be determined, since
these cells had been shown to be either pro- or anti-tumorigenic in
different experimental skin cancer models (Yusuf et al, 2008;
Kwong et al, 2010; Nasti et al, 2011).
Interestingly, we found a strong accumulation of macrophages in
K14-Act and K14-Act/HPV8 mice and also in pre-tumorigenic skin
of Act mice subjected to multiple TPA treatments. This is consistent
with in vitro data showing that activin attracts human monocytes
(Petraglia et al, 1991) and induces dendritic cell migration (Salogni
et al, 2009). The macrophage accumulation resulted from attraction
of CCR2+ blood monocytes to the skin. This is most likely a result
of the high diffusibility of activin (McDowell et al, 1997), resulting
in increased serum levels of activin A in Act mice (Munz et al,
1999). Therefore, activin can induce the expression of various genes
associated with cell migration/adhesion in blood monocytes.
Consistent with the in vivo data, activin A induced monocyte/
macrophage migration in vitro and upregulated the expression of
adhesion molecules and chemokine receptors on monocyte-derived
peritoneal macrophages, including Cx3cr1, which was shown to
mediate recruitment of macrophages into several types of tumors
(Held-Feindt et al, 2010; Schmall et al, 2015) and to increase macro-
phage survival during tumor metastasis (Zheng et al, 2013). There-
fore, activin may not only attract monocytes through upregulation
of this receptor, but also increase the survival of tissue
macrophages.
F4/80 and CD11b were used for isolation of skin macrophages to
obtain a broad coverage of macrophages and to allow isolation of a
sufficient number of these cells from the small ear skin samples. We
are aware of the limitations resulting from this sorting strategy, such
as the inclusion of Langerhans cells, and it will be important in the
future to further analyze the activin-induced gene expression profile
in different macrophage subpopulations. Nevertheless, the data
provide important novel insight into the gene expression profile of
skin macrophages and also demonstrate that activin reprograms
macrophages in vivo, resulting in a TAM-like phenotype. Thus,
activin is obviously a key factor in the control of macrophage
programming in the tumor microenvironment (Ruffell et al, 2012).
One of the activin-induced pro-tumorigenic genes encodes osteo-
pontin, whose expression in TAMs correlated with poor prognosis
in gastric cancer (Lin et al, 2015). Alternative translation of the
Spp1 mRNA results in intracellular or secreted variants of osteopon-
tin (Shinohara et al, 2008). Intracellular osteopontin is important
for migration of macrophages and innate immune receptor signaling
in myeloid cells, while the secreted variant is an important cytokine
in immune regulation and cancer (Inoue & Shinohara, 2011; Shevde
& Samant, 2014). It promoted angiogenesis and melanoma growth
(Rangaswami et al, 2004; Kale et al, 2014) as well as DMBA/TPA-
induced skin carcinogenesis in mice (Hsieh et al, 2006). This is
likely to be relevant for human skin cancer, since osteopontin is
expressed in the stroma of human AK and SCCs, and promotes
proliferation and survival of human keratinocytes (Luo et al, 2011).
Consistent with in vitro data (Ogawa et al, 2006), activin induced
the expression of arginase 1 in the skin in vivo. This enzyme
promoted tumorigenesis and keratinocyte proliferation in mice
expressing a constitutively active MEK mutant in suprabasal kerati-
nocytes, which develop tumors after skin wounding (Weber et al,
2016). Although arginase 1 is considered as a classical M2 marker,
the activin-dependent gene expression profile was positively corre-
lated with genes upregulated in the in vitro generated classically
activated human macrophages. This supports the findings that
activin contributes to GM-CSF-induced M1 macrophage polarization
and the pro-inflammatory phenotype of these cells (Sierra-Filardi
et al, 2011), and reflects a multipolar rather than bipolar view on
macrophage activation in vivo (Mosser & Edwards, 2008). Thus, as
in many in vivo models, TAMs in human SCCs showed signs of both
M1 and M2 polarization (Pettersen et al, 2011).
Finally, activin induced the expression of several MMPs, includ-
ing MMP-12, -13, and -14, resulting in increased proteolytic activity
in the skin. This is likely to be functionally relevant, since increased
levels of MMP-12 in myeloid cells promoted lung tumorigenesis in
mice and correlated with high malignancy in human lung cancer
(Hofmann et al, 2005; Qu et al, 2011). MMP-14 and its downstream
effector MMP-2 are major players in angiogenesis and tumorigenesis
(Kessenbrock et al, 2010), and MMP-13 promoted tumor angiogene-
sis, melanoma invasion, and metastasis (Zigrino et al, 2009; Kudo
et al, 2012). The activin-induced expression of these MMPs and of
additional pro-angiogenic genes in macrophages provides a likely
explanation for the strong increase in the number of blood vessels
in the vicinity of the epidermis of activin-overexpressing mice and
thus adjacent to the source of activin.
The important role of macrophages in activin-induced skin
tumorigenesis was finally demonstrated by the strong reduction in
tumor formation upon macrophage depletion. This is consistent
with the previously described reduction in tumorigenesis upon
CSF1R inhibition in mouse models for mammary (DeNardo et al,
2011), cervical (Strachan et al, 2013), and pancreatic (Zhu et al,
2014) carcinoma or in glioma (Pyonteck et al, 2013), or upon deple-
tion of macrophages by a DT approach or clodronate liposomes in a
wound-induced skin cancer model (Arwert et al, 2010; Weber et al,
2016). Since activin expression is strongly enhanced by skin wound-
ing (Hubner et al, 1996), the pro-tumorigenic effect of macrophages
in this skin tumor model may be at least in part activin-dependent.
In contrast, depletion of macrophages in a mouse model of BCC
promoted tumor growth (Konig et al, 2014), suggesting that the role
of macrophages is dependent on the type of tumor and most likely
also on the gene expression pattern of the macrophages.
The data presented in this manuscript also provide insight into
the mechanisms underlying the suppression of skin tumor devel-
opment by macrophage depletion, which involves a reduction in
blood vessel formation and tumor cell proliferation. These find-
ings are consistent with the functions of TAMs in existing malig-
nancies (Ruffell et al, 2012; Noy & Pollard, 2014), but also point
to a crucial role of macrophage-dependent keratinocyte prolifera-
tion and angiogenesis during the early development of skin
cancers. This is obviously not restricted to murine skin cancer,
since our bioinformatics analysis revealed overexpression of
INHBA in AK, together with various activin target genes in macro-
phages, which we had identified in our mouse model. Further-
more, expression of macrophage chemoattractant protein-1 and
macrophage infiltration are associated with angiogenic promotion
and poor prognosis in esophageal SCC (Koide et al, 2004), where
activin is also overexpressed (Yoshinaga et al, 2003), and with
malignant transformation of keratinocytes in human skin
(Takahara et al, 2009).
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Taken together, we have identified a novel role of activin in the
attraction of monocytes to the skin and their reprogramming into a
TAM phenotype, which is functionally important in early skin
tumorigenesis. This is likely to be potentiated by its action on other
cells of the tumor stroma, highlighting the strong effect of this factor
on the tumor microenvironment (Antsiferova & Werner, 2012). Our
results also suggest the exciting possibility of using antagonists of
activin or its receptors, which are in preclinical or clinical trials for
other indications (Chen et al, 2015; Raftopoulos et al, 2016), for
skin cancer prevention, for example, through local treatment of skin
cancer precursor lesions.
Materials and Methods
Human skin samples
Biopsies from normal human skin and from AK were obtained from
the Department of Dermatology, University Hospital Zurich, as part
of the Biobank project, approved by the local and cantonal institu-
tion review boards EK no. 647/800. Consenting patients with multi-
ple AKs and a history of skin cancers underwent shave biopsies
with a ring curette. Each sample was investigated by a board certi-
fied dermatopathologist (RD), who confirmed the diagnosis. Written
informed consent was received from all patients. All research on
human material abided by the Helsinki Declaration on Human
Rights.
Genetically modified mice
Act and HPV8 mice were described previously (Schaper et al, 2005).
Act mice (in CD1 background) were crossed with HPV8 mice (in
C57BL/6J or FVB1 background) to obtain double-transgenic
progeny. Mice of the F1 generation of this breeding were used for
the tumorigenesis experiments. Animals in tumor experiments were
checked twice per week for the development of skin tumors. They
were euthanized according to animal welfare regulations when a
single tumor had a diameter of more than 1 cm, when more than
one tumor of > 0.5 cm appeared, or when a tumor had an unfavor-
able localization (e.g., eye).
CD4KO and CCR2-sCFP-DTR mice (both in C57BL/6 background)
and their genotyping were described before (Rahemtulla et al, 1991;
Hohl et al, 2009).
Mice were housed under optimal hygiene conditions and main-
tained according to Swiss animal protection guidelines. All experi-
ments with mice had been approved by the local veterinary
authorities (Kantonales Veterina¨ramt Zu¨rich, Switzerland).
For all animal experiments, we used mice of the same age and
gender. The number of mice used for the individual experiments
was based on previous experience from us and from others with
similar studies (see e.g., Rolfs et al, 2015), taken into consideration
the variability of animal studies.
RNA isolation and qRT–PCR analysis
RNA was isolated using RNeasy Kits (Qiagen, Hilden, Germany),
including a proteinase K digestion step for isolation of RNA from
tissue biopsies and a DNase on-column digestion for all samples.
cDNA was synthesized using iScript Kit (Bio-Rad Laboratories,
Hercules, CA, USA). Relative gene expression was determined using
the Roche LightCycler 480 SYBR Green system (Roche, Rotkreuz,
Switzerland) and the primers listed in Appendix Table S2.
Histology and immunostaining
Skin and tumor biopsies were excised after the mice had been sacri-
ficed by CO2 inhalation. They were fixed in 95% ethanol/1% acetic
acid for subsequent paraffin embedding or directly frozen in tissue-
freezing medium (Leica Microsystems, Heerbrugg, Switzerland).
Hematoxylin/eosin (H&E) and immunofluorescence staining on
paraffin (7 lm) or frozen sections (4 or 10 lm) and activin A
immunohistochemistry were performed as described previously
(Antsiferova et al, 2011). For BrdU staining, mice were injected i.p.
with BrdU (250 mg/kg in 0.9% NaCl; Sigma, Munich, Germany)
and sacrificed 2 h after injection. Skin biopsies were stained with an
antibody against BrdU. Antibodies used for immunostaining are
listed Appendix Table S3. Images were acquired with Imager.A1
microscope equipped with an AxiocamMrm camera using Axiovi-
sion software (Carl Zeiss Inc., Jena, Germany) or with Pannoramic
250 Slide Scanner (3D Histech, Budapest, Hungary). The latter
allowed scanning of sections covering the complete ear. Overall, the
total area analyzed for each mouse ear was between 3,000 and
5,000 mm2, which corresponds to approximately 30 images taken
with a 20× objective.
The number of BrdU-positive, dTcR–positive, and bTcR-positive
cells per mm of basement membrane, the area of CD206 positive
staining, and the number of cells migrated in Transwell assay
were quantified using Openlab 3.1.5 (Improvision Ltd., Basel,
Switzerland) or ImageJ (NIH, Bethesda, MD, USA) software. The
area, number, and size of blood vessels and the proximity of
blood vessels to the basement membrane were quantified using
the automated Definiens software (Definiens AG, Munich,
Germany).
Isolation of epidermal and dermal cells for magnetic-activated
cell sorting and flow cytometry
Single cell suspensions of epidermal and dermal cells were prepared
using modified protocols described previously (Junankar et al,
2006; Kisielow et al, 2008). Briefly, mice were sacrificed, ears were
excised, separated along the cartilage, and the dorsal part was
discarded. Ventral ear skin was placed on 0.2% trypsin (Invitrogen,
Paisley, UK) in DMEM (Sigma) for 30 min in 37°C. After separation
of the dermis, the epidermis was cut into small pieces and placed in
0.2% trypsin in DMEM supplemented with 0.25 mg/ml of deoxyri-
bonuclease I (DNase I; Sigma) for 40 min at 37°C under continuous
shaking. For flow cytometry analysis of trypsin-sensitive epitopes,
ventral ear parts were placed overnight at 4°C on DMEM containing
1% penicillin/streptomycin (Sigma) and subsequently transferred to
10 mM EDTA in PBS. After 60-min incubation at 37°C, the
epidermis was separated from the dermis, washed in 2 mM CaCl2 in
PBS, cut into pieces, and placed in DMEM supplemented with
0.25 mg/ml of DNase I for 40 min at 37°C under continuous shak-
ing. Subsequently, DMEM supplemented with 10% FCS (Sigma)
was added, the cells were filtered through 70-lm nylon strainers
(BD Pharmingen, Allschwil, Switzerland), centrifuged at 300 g and
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4°C for 10 min, and resuspended in FACS buffer (0.5% BSA, 2 mM
EDTA in PBS).
To isolate cells from the dermis, the separated tissue was cut into
small pieces, placed in DMEM supplemented with 2.5 mg/ml colla-
genase II (Worthington, Lakewood, NJ, USA), 2.5 mg/ml collage-
nase IV (Invitrogen, Carlsbad, CA), and 0.25 mg/ml DNase I, and
incubated at 37°C for 30 min under vigorous shaking. The dermal
cell suspension was filtered through a 70-lm nylon strainer, centri-
fuged at 300 g at 4°C for 10 min, and resuspended in FACS buffer.
MACS sorting
Magnetic cell separation sorting of epidermal and dermal cell
suspensions was performed according to the recommendations of
the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany).
Dead Cell Removal Kit and CD45 MicroBeads were used to purify
keratinocytes from isolated epidermis.
Flow cytometry
To prevent non-specific antibody binding, cells were incubated for
10 min at 4°C with rat anti-mouse CD16/CD32 monoclonal anti-
body, clone 2.4G2 (BD Pharmingen), prior to staining with epitope-
specific antibodies for 30 min at 4°C. Antibodies used for flow
cytometry are listed in Appendix Table S4.
To exclude non-viable cells, Zombie Aqua, Zombie Red (Biole-
gend, San Diego, CA, USA), 7-amino-actinomycin (7-AAD; BD
Pharmingen), or Sytox Green (Invitrogen) were used according to
the manufacturer‘s instructions. Cells were analyzed using FACS
Calibur or LSRFortessa and sorted using FACS Aria IIIu equipped
with the CellQuestPro or FACSDiva softwares (BD Pharmingen).
Data analysis was performed using FlowJo software (Tree Star Inc.,
Ashland, OR, USA).
Isolation of resident and inflammatory mouse
peritoneal macrophages
Resident peritoneal macrophages were isolated from untreated mice.
To obtain inflammatory thioglycollate (TG)-elicited inflammatory
macrophages, mice were i.p. injected with 1 ml of 4% TG (BD
Pharmingen) 4 days before isolation. They were euthanized by CO2
inhalation, and the skin above the abdomen was cut and opened,
leaving the muscle layer intact. 5–10 ml of cold PBS was injected
into the peritoneal cavity, the abdomen was massaged to detach the
cells, and the peritoneal cells were collected with a syringe and a
pipet.
Isolation of mouse blood monocytes
Blood was drawn by cardiac puncture on 5 U/ml heparin and
pooled from 13 to 15 female CD1 mice. After erythrocyte lysis with
ACK lysis buffer (8.29 g NH4Cl, 1 g KHCO3, 2 ml of 0.5 M EDTA,
pH 7.3), the cells were blocked for 10 min at 4°C with rat anti-
mouse CD16/CD32 monoclonal antibody (BD Pharmingen) and
stained for 30 min at 4°C with 1 ml of antibody mix (Ly6G-FITC,
B220-FITC, CD3-PE, CCR3-PE, CD49b-PE, MHCII-BV510, CD45-PB)
to label neutrophils, B cells, T cells, eosinophils, NK cells, and
dendritic cells. CD45+ cells negative for the other markers
mentioned above were sorted into cold macrophage serum-free
medium (Invitrogen). The purity of the sorted cells was above 88%.
70–90% of sorted cells expressed CD11b.
Transwell migration assay
Six hundred microliter of macrophage serum-free medium (M-SFM,
Invitrogen) containing recombinant human activin A (R&D Systems,
Minneapolis, MN) at various concentrations was placed into the
lower wells of transwell plates (Corning Incorporated, Corning, NY)
with 6.5 mm diameter inserts and 8.0 lm pore size. Macrophages
(105 per well, in duplicates) were seeded in 100 ll of M-SFM (with
or without activin A) on the inserts. After 24 h, the inserts were
removed from the plate and the upper side was cleaned with cotton
swabs to remove non-migrated cells. Following fixation in cold
100% methanol for 10 min, inserts were stained with only Hoechst
or together with F4/80-Alexa Fluor488 (Biolegend) for 1–3 h. After
washing with PBS, membranes from inserts were cut out, placed on
the glass slides, and mounted with Mowiol. The number of migrated
cells was counted by blinded investigators in five 10× or 20× micro-
scope fields and normalized to control (M-SFM).
FACS sorting and RNA sequencing
Dorsal and ventral parts of the mouse ears were separated, minced
with scissors, and digested with 0.25 mg/ml Liberase TL (Roche) in
DMEM for 1 h at 37°C. Following digestion, the cell suspension was
filtered through a 70-lm nylon strainer, centrifuged at 300 g at 4°C
for 10 min, and resuspended in FACS buffer. Ear skin macrophages
were enriched by FACS of CD45+F4/80+CD11b+ cells from the
non-cancerous ear skin of 12- to 15-week-old mice. For each repli-
cate, ear skin from 3 to 6 mice per genotype was pooled. CD3 and
CD140a were used as additional negative markers. Dead cells were
excluded by Sytox Green staining. The purity was above 90%, as
determined by re-analysis of the sorted cells. Cells (50–200 × 103
per sample) were sorted into cold empty Eppendorf tubes, centri-
fuged, and total RNA was isolated on the same day using the
RNeasy Micro Kit (Qiagen, Hilden, Germany). RNA quality was
determined on a TapeStation (Agilent, Santa Clara, CA, USA), and
RIN varied from 5.1 to 6.9. RNA concentration was measured with a
Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA),
and 12 ng total RNA was used for library preparation. After riboso-
mal RNA depletion using the Ribo-Zero Magnetic Kit (Epicentre/Illu-
mina, Madison, WI, USA) and a modified Protocol For Truly Low
Input Total RNA Samples (Clontech, Mountain View, CA, USA), the
SMARTer Stranded RNA-Seq Kit (Clontech) was used according to
the manufacturer‘s instructions. The quality of amplified libraries
was validated using a TapeStation (Agilent). Concentrations of
labeled fragments were measured using absolute quantification
qPCR with primers specific to Illumina sequencing adapters.
Libraries were sequenced on an Illumina Hiseq 2500 v3. Approxi-
mately 20 million reads were generated per sample.
Bioinformatic analysis of RNA-Sequencing data
Raw reads were first cleaned by removing adapter sequences, trim-
ming low quality ends (four bases from read start and read end),
and filtering reads with low quality (phred quality < 20) using
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Trimmomatic (Bolger et al, 2014). Sequence alignment and isoform
expression quantification of the resulting high-quality reads to the
Mus musculus reference genome (build GRCm38) was performed
with the RSEM algorithm (Li & Dewey, 2011) (version 1.2.18) with
the option for estimation of the read start position distribution
turned on. To detect differentially expressed genes, we applied the
count based negative binomial model implemented in the software
package edgeR (version: 3.10.2) (Robinson et al, 2010), in which
the normalization factor was calculated by the trimmed mean of M
values (TMM) method (Robinson & Oshlack, 2010). The gene-wise
dispersions were estimated by conditional maximum likelihood, and
an empirical Bayes procedure was used to shrink the dispersions
toward a consensus value. Differential expression was assessed
using an exact test adapted for over-dispersed data. Genes showing
altered expression with adjusted (Benjamini and Hochberg method)
P-value (false discovery rate, FDR) ≤ 0.05 were considered as dif-
ferentially expressed. Lists of differentially expressed genes were
further filtered to eliminate those genes whose normalized count
was 0 in more than one sample. Venny 2.1.0 (http://bioinfogp.cnb.c
sic.es/tools/venny/index.html) was used to find and visualize via a
Venn diagram the common genes among the significantly differen-
tially expressed genes. Lists of differentially expressed genes from
all genotype comparisons are provided in Dataset EV2. The original
data have been deposited in NCBI‘s Gene Expression Omnibus and
are accessible through GEO Series accession number GSE79086.
Ingenuity pathway analysis
Lists of differentially expressed genes of all three genotype compar-
isons (wt/Act vs. wt/wt; HPV8/Act vs. HPV8/wt; HPV8/Act vs.
wt/wt) were uploaded into IPA (Qiagen), and identical core analy-
ses using confidence of only “experimentally observed” relation-
ships were run with filtered lists of up- and downregulated genes
that exhibited an FDR value of < 0.1. Analysis-ready differentially
expressed genes for each analysis were 179 for wt/Act vs. wt/wt,
207 for HPV8/Act vs. HPV8/wt, and 379 for HPV8/Act vs. wt/wt. A
comparison analysis of the three core analyses was performed, and
the data tables associated with “Diseases & Functions” were
exported to identify the most highly activated and most highly
significantly enriched functions or diseases in the three genotype
comparisons. Selected functions or diseases were arranged in a
spreadsheet, and their activation z-scores were color-coded in a
pseudo-heatmap for visualization. Original IPA output data with
unfiltered “Diseases & Functions” for all comparisons are provided
in Dataset EV3.
Gene set enrichment analysis
Sets of the most highly significantly upregulated (top) and down-
regulated (bottom) genes were generated from published microar-
ray data. The datasets, samples, and methods for obtaining the
gene sets are listed in Appendix Table S5. Original gene sets were
uploaded to GSEA and filtered to those mapped by gene symbol
present in the dataset being tested. The first gene sets were tested
against the GSEA-generated ranked gene lists of each of the three
genotype comparisons (n = 3; wt/Act vs. wt/wt, HPV8/Act vs.
HPV8/wt, HPV8/Act vs. wt/wt) and a comparison that grouped all
Act vs. wt samples (n = 6; [all]/Act vs. [all]/wt). Subsequent gene
sets were tested against GSEA-generated gene lists of the [all]/Act
vs. [all]/wt comparison, and two microarrays of human AK vs.
normal skin downloaded from the Gene Expression Omnibus
(GEO): GSE2503 and GSE63107. GSEA was performed using the
following settings:
Number of permutations 2,000
Permutation type Gene Set
Enrichment statistic Weighted
Metric for ranking genes Signal2Noise
Gene list sorting mode Real
Normalization mode Meandiv
Randomization mode No_balance
Omit features with no symbol match True
Two separate GSEA runs were completed (i) testing all genotype
comparisons against TAM gene sets and (ii) testing the [all]/Act vs.
[all]/wt comparison and two human AK vs. normal skin transcrip-
tomes against respective top upregulated gene sets, macrophage
polarization gene sets, and selected myeloid/lymphoid cell-type-
specific gene expression profiles. GSEA results were organized in
tables, and the normalized enrichment scores were color-coded in
pseudo-heatmaps for visualization. Original and filtered gene sets,
ranked gene lists, and original GSEA output data for all experiments
are provided in Dataset EV4.
Preparation of protein lysates and Western blotting
Frozen tissue was homogenized in T-PER tissue protein extraction
reagent (Pierce, Rockford, IL, USA) containing complete protease
inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail
(Roche). Lysates were cleared by sonication and centrifugation.
Protein lysates were analyzed by Western blotting using osteopontin
(R&D Systems) or GAPDH antibodies (HyTest, Turku, Finland).
Antibody-bound proteins were detected using horseradish peroxi-
dase coupled antibodies against goat-IgG (Calbiochem, San Diego,
CA, USA) or mouse-IgG (Promega, Du¨bendorf, Switzerland).
Gelatin zymography
Gelatin in situ and in-gel zymography were performed as previously
described (Kurschat et al, 2002).
Macrophage depletion in vivo
K14-Act/K14-HPV8 mice (CD1/FVB1 F1 background) were injected
i.p. with 50 mg/kg anti-CSF1R antibody (clone AFS98, BioXCell,
Upper Heyford, UK) or control rat IgG (Sigma) twice per week for
5 weeks, starting at the age of P30–P36. Only mice without obvious
signs of dysplasia at the beginning of treatment were included in the
experiment. Among those, randomization was performed by an
investigator, who had not seen the mice, by assigning the mice to
different treatment groups using the individual mouse identity
number (even numbers—control IgG; odd numbers—anti-CSF1R).
Signs of tumorigenic growth (scaling, hyperproliferation, ulceration)
were monitored twice per week by two investigators kept blinded to
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the assigned treatment. Lesions persisting for more than 2 weeks
were recorded as tumors.
Statistical analysis
Statistical analysis was performed using the PRISM software,
version 5.0a or 7 for Mac OS X or Windows (GraphPad Software
Inc., San Diego, CA, USA). For comparison of two groups, Mann–
Whitney test was performed; for comparison of more than two
groups, one-way ANOVA and Bonferroni’s multiple comparisons
test was used; for analysis of tumor incidence, a log-rank (Mantel–
Cox) test was performed. Statistical analysis of fold-change data was
performed after log-transformation. For migration data, when
several independent experiments were combined, each of them
being normalized to corresponding control, one-sample t-test was
used after log-transformation. For all experiments, the variance was
similar between the groups that were statistically compared.
Expanded View for this article is available online.
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